Synchron

Synchron is a pioneering neurotechnology company dedicated to restoring human agency through the development of minimally invasive, implantable brain-computer interfaces (BCIs). Unlike traditional BCI approaches that require invasive open-brain surgery, Synchron utilizes a proprietary endovascular method to deliver its Stentrode™ device via the jugular vein. This technology allows patients with severe motor impairments to control digital devices, such as computers and smartphones, directly through neural signals, significantly improving their ability to communicate and interact with the world.

Mission: To restore, extend and protect human agency. Vision: Near-term, release motor models that improve agency for 15 million people with motor impairment; long-term, release general cognition models that improve agency for 500 million people with cognitive decline.

• First company to receive an FDA Investigational Device Exemption (IDE) for a permanently implanted BCI in 2021
• Successfully implanted the Stentrode™ device in patients across both Australia and the United States
• Backed by high-profile investors including ARCH Venture Partners, Bezos Expeditions, and Gates Frontier
• Pioneered a non-craniotomy approach to brain-computer interfacing

Sources

• Synchron Official Website
• FDA Regulatory Filings